

Table 4. Postprandial blood glucose (mg/dL).

Time	Measure	Glibenclamide	Insulin	^P-value	Effect size
		(N=60)	(N=60)		Mean±SE 95% CI
Baseline	Mean±SD	194.8±31.1	192.1±28.4	0.625	2.7±5.4
	Range	135.0–259.0	134.0–254.0		-8.1–13.4
Week 30-32	Mean±SD	148.6±17.9	143.3±21.1	0.145	5.3±3.6
	Range	116.0–182.0	112.0–183.0		-1.8–12.3
Week 36-38	Mean±SD	136.3±14.2	132.4±9.7	0.079	3.9±2.2
	Range	112.0–177.0	106.0–154.0		-0.5–8.3
Change at week 30-32	Mean±SD	-46.2±20.8	-48.8±22.3	0.513	2.6±3.9
	Range	-105.0--12.0	-108.0--8.0		-5.2–10.4
Change at week 36-38	Mean±SD	-58.5±20.3	-59.8±20.8	0.736	1.3±3.7
	Range	-103.0--19.0	-110.0--17.0		-6.2–8.7

^Independent t-test. Effect size: Value of Glibenclamide relative to insulin. SE: Standard error. CI: Confidence interval.

Change=follow up - baseline, negative values indicate reduction.